Prof Ali Bazarbachi speaks to ecancer about the real-world evidence on the use of antibody-drug conjugates in peripheral T-cell lymphoma.
Initially, he discusses the recent studies and the real-world evidence regarding the use of antibody-drug conjugates in peripheral T-cell lymphoma.
He further explains the results from ECHELON-2; 5-Year results of a randomised, double-blind, phase 3 study of frontline brentuximab vedotin + CHP VS CHOP in patients with CD30-positive peripheral T-cell lymphoma and what it means for the future of PTCL.
In the end, he mentions a few other studies presented in the last few years of significance regarding the use of ADCs for PTCL.
|5-year results of ECHELON-2 study|
|Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma|
|Studies regarding the use of brentuximab vedotin for peripheral T-cell lymphoma|
This programme has been supported by an unrestricted educational grant from Takeda.